Tatva Chintan Pharma Chem Ltd

Resignation of Senior Management

• Mr. Ajay Rawat, AVP - Research and Development, resigns as Senior Management Personnel.
• Resignation accepted by the company on 19 August 2026.
• Cessation effective from close of business hours on 13 November 2026.
• Reason for change disclosed in attached resignation letter.
• Disclosure of relationships with other directors: Not Applicable.

Dividend announcement

• Board recommended final dividend of Rs 2.00 per equity share (20%) for FY2025-26.

Payout timing and AGM condition

• Dividend payable only if shareholders approve at the upcoming 30th AGM.
• Payment to holders on record date, subject to AGM approval.

Tax withholding framework

• Resident TDS: 10% on dividends with PAN; NIL/low with eligible declarations.
• Non-residents: 20% plus surcharge/cess; DTAA benefits require documents.

Documentation & deadlines

• Declarations and documents required for TDS eligibility must be submitted.
• Deadline to submit: 10 September 2026; via RTA portal.

Shareholder data updates

• Update PAN/Aadhaar linkage, email, and bank details with RTA/depositories.

Communication and record-keeping

• Website publication of the communication; no further updates post deadline.

Dahej III greenfield unit

• Groundbreaking ceremony held on 20 July 2026 for Dahej III at Dahej Industrial Estate, Vagra, Bharuch, Gujarat.
• New facility to strengthen infrastructure and meet growing market demands under the growth strategy.

Meeting details

• Date and time: 17 July 2026 at 05:00 p.m. IST.
• Type and mode: group earnings call conducted virtually.
• Organiser: Tatva Chintan Pharma Chem Limited.
• Key company participant: Company Secretary and Compliance Officer.
• Purpose: earnings results discussion.
• Recording available on the company's website.

Business Overview

• Integrated specialty chemicals firm with four product categories: PTC, SDA, ESS, PASC.
• Green chemistry focus via electrolysis and continuous flow processes.
• Exports account for a majority of revenue; 25+ countries served.
• Subsidiaries in USA and Netherlands support global operations.

Operational Highlights

• FY26 revenue from operations ₹5,059 Mn; YoY growth 32%.
• Q1FY27 revenue ₹1,671 Mn; YoY growth 43%.
• Q1FY27 EBITDA excluding other income ₹323 Mn; margin 19%.
• FY26 EBITDA excluding other income ₹932 Mn; margin 18%.
• FY26 PAT ₹421 Mn; PAT margin ~8%.
• FY26 product mix: SDA 41%, PASC 32%, PTC 23%, ESS 3%.
• Combined installed capacity 791 KL and 39 assembly lines as of 31 Mar 2026.
• Exports to 25+ countries; warehousing in Amsterdam and Savanna.

Financial Performance

• FY26 EBITDA ₹932 Mn; EBITDA margin 18%.
• FY26 PAT ₹421 Mn; PAT margin 8%.
• Q1FY27 Revenue ₹1,671 Mn; EBITDA ₹323 Mn; margin 19%.
• Q1FY27 PAT ₹160 Mn; margin ~10%.
• EPS (Q1FY27) ₹17.98.

Capital Structure & Liquidity

• Promoter stake 72.02%; public 19.88%; FPIs 3.93% as of June 2026.
• QIP raised ₹200 crore in 2023.
• Debt-to-equity ratio 1.29x in FY26.
• Cash and cash equivalents ₹87.9 Mn as of 31-Mar-26.
• Credit rating CRISIL BBB+/Stable and A2.

Strategic Priorities & Outlook

• Capex to boost capacities and drive higher revenues.
• Green chemistry emphasis; electrolysis and continuous flow enhance margins.
• Global expansion via USA and Netherlands subsidiaries; 25+ export markets.
• DSIR-recognized R&D center at Vadodara with 56 staff.

Risks & Mitigation

• Regulatory, R&D, and COVID-19 related risks acknowledged.
• Mitigation through in-house DSIR-recognized R&D, green chemistry, and diversified end-use markets.

Governance & Leadership

• MD: Chintan Shah; WTDs: Ajaykumar Patel, Shekhar Somani.
• Independent Directors: Subhash Patel, Dr. Avani Umatt, Dr. Manher Desai.
• Listed on NSE/BSE since 2021; QIP raised in 2023.

Financial results

• Unaudited standalone and consolidated results for quarter ended 30 June 2026 approved.
• Limited Review Reports by NDJ & Co. accompany the results.

Director and management changes

• Chintan Shah re-appointed as Managing Director for 2027–2030, subject to AGM.
• Ajaykumar Patel re-appointed as Whole-time Director for 2027–2030, subject to AGM.
• Shekhar Somani re-appointed as Whole-time Director for 2027–2030, subject to AGM.

Capacity expansion

• Dahej III greenfield unit capacity expansion approved; 344 KL reactor capacity.
• Investment about Rs 200 Crores; financing via internal accruals and debt.

Financing and borrowing

• Borrowing limit raised to Rs 1000 Crores from Rs 300 Crores; subject to Members’ approval.

Auditor remarks and disclosures

Meeting Details

• Date and time: 17 July 2026 at 05:00 p.m. IST.
• Type and mode: earnings conference call (virtual).
• Organizer: ICICI Securities.
• Event: Q1FY27 Results Conference Call.

Purpose

• Discuss Q1 FY27 earnings results with investors.

Participants

• Managing Director and Chief Financial Officer.

Additional Notes

• Information will be uploaded on the company website.
• Registration details provided by ICICI Securities for the call.